Daniel H. Ahn, DO

Articles

Dr. Ahn on the Increased Understanding of Cholangiocarcinoma

October 8th 2021

Daniel H. Ahn, DO, discusses the increased understanding of cholangiocarcinoma.

Dr. Ahn on Navigating Among Available Therapeutic Options in Advanced, Unresectable HCC

June 22nd 2021

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

Dr. Ahn on Treatment Considerations With Atezolizumab/Bevacizumab in Unresectable HCC

June 21st 2021

Daniel H. Ahn, DO, discusses considerations for treatment with atezolizumab and bevacizumab in patients with hepatocellular carcinoma.

Dr. Ahn on the Utility of Atezolizumab/Bevacizumab in HCC

June 17th 2021

Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.

Dr. Ahn on the Growing Role of ctDNA as a Biomarker in CRC

January 21st 2021

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

Dr. Ahn on the Role of Checkpoint Inhibitors in NTRK Fusion+ MSI-H CRC

November 10th 2020

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Dr. Ahn on the Identification of NTRK Alterations in CRC

October 30th 2020

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Dr. Ahn on the Significance of the KEYNOTE-177 Trial in mCRC

October 27th 2020

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Dr. Ahn on the Evolution of Targetable Alterations in CRC

October 23rd 2020

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Dr. Ahn on Limitations of Targeted Therapy in CRC

July 24th 2020

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Dr. Ahn on the KEYNOTE-177 Trial in Newly Diagnosed MSI-H/dMMR mCRC

July 23rd 2020

Daniel H. Ahn, DO, discusses ​updated findings from the ​phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.

Dr. Ahn on Advancing Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.

Dr. Ahn on Left- Versus Right-Sided Tumors in CRC

July 13th 2020

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Dr. Ahn on Biomarker-Driven Strategies in Gastric/GEJ Cancers

August 15th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.

Dr. Ahn on Targeted Therapies in Gastric/Gastroesophageal Cancers

May 24th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric/esophageal cancers.

Dr. Ahn on the Role of Immunotherapy in Treating Patients With Gastric/Gastroesophageal Cancers

May 11th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses the role of immunotherapy in treating patients with gastric/gastroesophageal cancers.

Dr. Ahn on Neoadjuvant Treatments for Patients With Gastric Cancer

March 13th 2017

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.

Dr. Ahn on Novel Biomarkers in Gastric Cancer

February 28th 2017

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses the identification of novel biomarkers in gastric cancer during the 2017 State of the Science Summit on Gastrointestinal Malignancies.